PT  - JOURNAL ARTICLE
AU  - Nell, R.J.
AU  - Versluis, M.
AU  - Cats, D.
AU  - Mei, H.
AU  - Verdijk, R.M.
AU  - Kroes, W.G.M.
AU  - Luyten, G.P.M.
AU  - Jager, M.J.
AU  - van der Velden, P.A.
TI  - Identification of clinically-relevant genetic alterations in uveal melanoma using RNA sequencing
AID  - 10.1101/2023.12.03.23299340
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.12.03.23299340
4099  - http://medrxiv.org/content/early/2023/12/05/2023.12.03.23299340.short
4100  - http://medrxiv.org/content/early/2023/12/05/2023.12.03.23299340.full
AB  - Introduction Uveal melanoma is a lethal intraocular tumour, in which the presence of certain genetic alterations correlates with the risk of metastatic dissemination and patient survival. RNA data is typically used to transcriptionally characterise tumours and their micro-environment. In this study, we tested the detectability of all key genetic alterations in uveal melanoma from RNA sequencing data.Methods Cohort-wide gene expression profiling was used to classify tumours at the transcriptional level. In individual samples, copy number alterations affecting chromosomes 3 and 8q were analysed by measuring expressed allelic imbalances of heterozygous common single nucleotide polymorphisms. Mutations in GNAQ, GNA11, CYSLTR2, PLCB4, BAP1, SF3B1 and EIF1AX were identified by screening of hotspot regions and by evaluating their transcriptional effects. All findings were cross-validated with DNA-derived data in a training cohort of 80 primary uveal melanomas studied by The Cancer Genome Atlas (TCGA) initiative, and in five prospectively analysed cases from our institution.Results Unsupervised gene expression profiling strongly correlated to the presence of chromosome 3 alterations, but was not reliable in identifying other (clinically-)relevant genetic alterations. However, the presence of both chromosome 3 and 8q copy number alterations could be successfully inferred from expressed allelic imbalances in most tumours. The majority of mutations were adequately recognised at the RNA level by their nucleotide changes (all genes), alternative splicing around the mutant position (BAP1) and transcriptome-wide aberrant splice junction usage (SF3B1). Notably, in the TCGA cohort we detected previously unreported mutations in BAP1 (n=3) and EIF1AX (n=5), that were missed by the original DNA sequencing. In our prospective cohort, all mutations and copy number alterations were successfully identified at the RNA level by combining the described approaches.Conclusion In addition to providing gene expression levels and profiles, RNA from uveal melanomas presents insights into the expressed tumour genotype and its phenotypic consequences. Such complete analysis of transcriptional data may augment or even substitute current DNA-based approaches, and has potential applicability in both research and clinical practice.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partly funded by the European Union's Horizon 2020 research and innovation program under grant agreement number 667787 (UM Cure 2020, Rogier J. Nell).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Ethics committee/IRB of Leiden University Medical Center (LUMC Biobank Committee and Medisch Ethische Toetsingscommissie, numbers B14.003/SH/sh and B20.026/KB/kb) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThis work is partly based upon data generated by The Cancer Genome Atlas (TCGA) Research Network: https://www.cancer.gov/tcga. All data produced in the study are contained in the manuscript and supplement. https://github.com/rjnell/um-rna